Financial Performance - The estimated net profit for the first half of 2024 is projected to be between 24,600,000 and 28,000,000 CNY, representing a year-on-year increase of 126.39% to 157.68% compared to 10,866,040 CNY in the same period last year[4]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 17,506,830 and 19,631,830 CNY, reflecting a growth of 85.86% to 108.42% from 9,419,440 CNY in the previous year[4]. - The basic earnings per share are anticipated to be between 0.20 CNY and 0.23 CNY, compared to 0.09 CNY per share in the same period last year[4]. Factors Contributing to Profit Growth - The significant increase in net profit is attributed to the initial market deployment of new and existing proprietary pharmaceutical products, leading to a higher growth rate in sales gross profit compared to expense growth[7]. - The company has also received increased government subsidies related to revenue, contributing to the profit growth[7]. Financial Reporting - The financial data presented is preliminary and has not yet been audited by an accounting firm, with final figures to be disclosed in the company's 2024 semi-annual report[10].

证券代码：002019 证券简称：亿帆医药 公告编号：2024-034 亿帆医药股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 7、证书编号：2024S00957 8、药品批准文号：国药准字H20243815 9、药品批准文号有效期：至2029年05月27日 亿帆医药股份有限公司（以下简称"公司"）全资子公司合肥亿帆生物制药 有限公司于2024年6月3日收到国家药品监督管理局核准签发的间苯三酚注射液 《药品注册证书》。现将相关情况公告如下： 一、药品注册证书主要信息 1、药品名称：间苯三酚注射液 2、剂型：注射剂 3、申请事项：药品注册（境内生产） 4、注册分类：化学药品4类 5、规格：4ml:40mg（按C₆H₆O₃·2H₂O计） 6、药品受理号：CYHS2201905 10、上市许可持有人：合肥亿帆生物制药有限公司 11、生产企业：合肥亿帆生物制药有限公司 12、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、产品简介 间苯三酚注射液适用 ...

| --- | --- | --- | --- | --- | --- | |-------|----------------------------|----------------------|--------------|-------------|----------------------| | 区域 | [Table_SalesPerson] 姓名 | 职务 | 座机 | 手机 | 邮箱 | | | 蒋诗烽 | 总经理助理、销售总监 | 021-68415309 | 18621310081 | jsf@swsc.com.cn | | | 崔露文 | 销售副总监 | 15642960315 | 15642960315 | clw@swsc.com.cn | | | 谭世泽 | 高级销售经理 | 13122900886 | 13122900886 | tsz@swsc.com.cn | | | 汪艺 | 高级销售经理 | 13127920536 | 13127920536 | wyyf@swsc.com.cn | | | 李煜 | 高级销售经理 | 18801732511 | 18801732511 ...

Investment Rating - The report maintains a "Buy" rating for Yifan Pharmaceutical (002019 SZ) [20] Core Views - Yifan Pharmaceutical's Q1 2024 performance exceeded market expectations, driven by strong growth in the pharmaceutical sector [6] - The company's revenue for Q1 2024 reached 1 3 billion yuan, a year-on-year increase of 41 28%, with net profit attributable to shareholders of 146 million yuan, up 125 55% [6] - The company's cost reduction and efficiency improvement efforts have significantly contributed to profit growth, with sales expense ratio dropping to 23 74% and management expense ratio to 6 75% in Q1 2024 [6] - The company's "big product" strategy is paying off, with domestic pharmaceutical product revenue reaching 2 01 billion yuan in 2023, a 21 72% increase [6] - The innovative drug Yilisu has completed registration in China, the US, and Europe, and is expected to contribute 72 million yuan in milestone revenue in 2024 [6] - The company's R&D investment continues to grow, with Q1 2024 R&D expenses reaching 59 88 million yuan, a 26% year-on-year increase [6] Financial Performance - The company's revenue is expected to grow from 4 882 billion yuan in 2024E to 7 567 billion yuan in 2026E, with a CAGR of 24 5% [2] - Net profit attributable to shareholders is forecasted to increase from 552 million yuan in 2024E to 922 million yuan in 2026E, with a CAGR of 29 1% [2] - The company's EPS is projected to grow from 0 45 yuan in 2024E to 0 75 yuan in 2026E [2] - ROE is expected to improve from 5 8% in 2024E to 8 4% in 2026E [2] - The company's P/E ratio is forecasted to decrease from 28 1x in 2024E to 16 8x in 2026E, indicating potential undervaluation [2] Product Pipeline - Yilisu, the company's innovative drug, has a potential market size of 7 billion USD and is expected to achieve peak sales of over 5 billion yuan [6] - F652 is progressing well in clinical trials, with the ACLF indication expected to complete key clinical trial design and initiate patient enrollment in 2024 [6] - Hyruan ONE, a cross-linked sodium hyaluronate injection, was approved in China in April 2023 and included in the national medical insurance catalog in December 2023, with potential peak sales of 2 billion yuan [6] - The company has two products in pre-clinical stages for the US and European markets, and three third-generation insulin products in pre-clinical stages [6] Strategic Initiatives - The company plans to have 2 products with overseas sales exceeding 100 million yuan and 4 products with sales exceeding 50 million yuan by 2024 [6] - Domestically, the company aims to have 9 products with sales exceeding 100 million yuan and 9 products with sales exceeding 50 million yuan by 2024 [6] - The company expects to have its first synthetic biology product ready for trial production by the end of 2024 [6]

Financial Performance - Net profit for the quarter was ¥117,548,462.21, compared to ¥43,990,187.10 in the same period last year, reflecting a significant increase of approximately 167.0%[1] - The net profit attributable to shareholders increased by 125.55% year-on-year, with a net profit excluding non-recurring gains and losses growing by 83.93%[22] - The company's operating revenue for the reporting period reached ¥1,325,969,392.93, representing a year-on-year increase of 41.28%[46] - The total comprehensive income for the first quarter of 2024 was CNY 103,628,790.72, compared to CNY 26,357,285.27 in the same period last year, indicating a significant increase[65] - The net income attributable to the parent company for the first quarter was CNY 132,186,331.58, up from CNY 47,666,310.90 year-over-year[65] Operating Costs and Expenses - Total operating costs for the first quarter reached ¥1,189,455,724.43, an increase from ¥892,797,132.61 in the previous year, representing a growth of approximately 33.2%[1] - Research and development expenses amounted to ¥59,876,908.40, up from ¥47,510,975.21, indicating a year-over-year increase of about 26.0%[1] - Cash paid for goods and services was ¥516,532,728.18, compared to ¥509,033,106.83 in the previous period, showing a slight increase of about 1.0%[42] Cash Flow and Liquidity - The company reported a net cash inflow from operating activities of ¥180,839,724.48, a substantial rise from ¥2,042,875.34 in the previous year[3] - The net cash flow from operating activities surged to ¥180,839,724.48, marking an extraordinary increase of 8,752.22% compared to the previous year[46] - Cash and cash equivalents at the end of the period totaled ¥688,839,805.94, down from ¥794,222,368.09, marking a decrease of about 13.3%[3] - The company’s cash and cash equivalents at the end of the reporting period were approximately 810.56 million RMB, up from 698.37 million RMB at the beginning of the period[38] Assets and Liabilities - Total current assets increased to ¥3,537,066,066.19 from ¥3,251,142,647.73, showing a growth of approximately 8.8%[39] - Total liabilities increased to ¥3,431,956,993.82 from ¥3,244,679,252.50, reflecting a rise of about 5.8%[40] - The company's total owner's equity increased to ¥8,349,206,466.80 from ¥8,254,906,529.64, representing a growth of approximately 1.1%[40] - The company recorded a decrease of 66.67% in trading financial assets, dropping to ¥25,000,000.00 from ¥75,010,256.50, primarily due to the maturity of financial products[14] Government Subsidies and Support - The company received government subsidies amounting to ¥1,434,862.57, which are closely related to its normal business operations[13] - The company received government subsidies related to income amounting to 28.50 million RMB, accounting for 14.90% of the audited net profit attributable to shareholders for the year 2022[37] - The company received government subsidies amounting to ¥43,729,939.86 during the reporting period, which contributed to the increase in other income[47] - The company is actively pursuing government subsidies to support its operations and growth initiatives[61] Shareholder and Management Activities - The company plans to increase shareholdings by directors and senior management, with a total investment of no less than 30 million RMB and no more than 50 million RMB within six months starting from February 2, 2024[33] - A total of 220 directors and senior management personnel increased their shareholding by 3,013,400 shares, representing 0.25% of the total share capital[58] - The company's controlling shareholder, Cheng Xianfeng, notified that part of his shares has been pledged and released, which may impact shareholder confidence[61] Product Development and Innovation - The subsidiary received a drug registration certificate for a new product, indicating ongoing product development and regulatory approval efforts[31] - The company’s subsidiary received a high-tech enterprise certificate, reaffirming its commitment to innovation and technology development[36] - The company introduced new pharmaceutical products, leading to a substantial increase in sales and contributing to the overall revenue growth[50] - The company’s wholly-owned subsidiary received approval for the registration of a new traditional Chinese medicine product in Singapore, enhancing its market presence[57] Impairment and Losses - The company reported a significant increase in credit impairment losses of 12,922.04%, attributed to the increased provision for bad debts based on aging of receivables[26] - Asset impairment losses rose by 250.94%, mainly due to increased provisions for inventory impairment during the reporting period[26] Miscellaneous - The first quarter report is part of the company’s ongoing commitment to transparency and regular updates to stakeholders[75] - The company’s total assets and liabilities will be detailed in the upcoming audited financial statements, as the current report is unaudited[67]

| --- | --- | --- | --- | --- | |-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

关于审计委员会对会计师事务所 2023 年度履行监督职责情 况的报告 亿帆医药股份有限公司 根据公司《审计委员会议事规则》等有关规定，审计委员会对会计师事务所 履行监督职责的情况如下： （一）审计委员会对立信会计师事务所的专业资质、业务能力、诚信状况、 独立性、过往审计工作情况及其执业质量等进行了严格核查和评价，认为其具备 为公司提供审计工作的资质和专业能力，能够满足公司审计工作的要求。2023年 4月13日召开的第八届董事会审计委员会2023年第三次会议审议通过了《关于续 聘立信会计师事务所（特殊普通合伙）为公司2023年度审计机构的议案》，同意 聘任立信会计师事务所为公司2023年度财务报表和内部控制审计机构，并同意提 交公司董事会审议。 亿帆医药股份有限公司（以下简称"公司"）聘用立信会计师事务所（特殊普 通合伙）（以下简称"立信会计师事务所"）作为公司2023年度年报审计机构。根 据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》 《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公司 自律监管指引第1号——主板上市公司规范运作》和《公司章程》等规定和要求， 董事会 ...

第二章 人员组成 | 第一章 | 总 则 2 | | --- | --- | | 第二章 | 人员组成 3 | | 第三章 | 职责权限 3 | 战略委员会议事规则 | 第四章 | 会议的召开与通知 4 | | --- | --- | | 第五章 | 会议的议事与表决程序 5 | | 第六章 | 附 则 7 | 第一章 总 则 第一条 为适应公司战略发展需要，增强公司核心竞争力，确定公司发展规 划，健全投资决策程序，加强决策科学性，提高重大投资决策的效益和决策的质 量，完善公司的治理机构，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《上市公司治理准则》《上市公司独立董事管理办法》《亿帆医药股份有限公司章 程》（以下简称"《公司章程》"）及其他有关规定，公司特设立董事会战略委员会 （以下简称"战略委员会"），并制定本议事规则。 战略委员会议事规则 第二条 董事会战略委员会是董事会按照股东大会决议设立的专门工作机 构，主要负责对公司长期发展战略和重大投资决策进行研究并提出建议。 第三条 战略委员会成员由五名董事组成，其中应至少包括二名独立董事。 第四条 战略委员会委员由董事会选举并由全体董事的过半数通 ...

关于举行 2023 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司定于2024年5月7日（星期二）15:00-17:00在全景网举 办2023年度网上业绩说明会，本次年度业绩说明会将采用网络远程的方式举行， 投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年度 业 绩 说 明 会 或 者 直 接 进 入 亿 帆 医 药 股 份 有 限 公 司 路 演 厅 （https://ir.p5w.net/c/002019.shtml）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长兼总裁程先锋先生、董事兼副总裁林 行先生、副总裁李锡明先生、副总裁耿雨红女士、财务总监张大巍先生、独立董 事刘洪泉先生、董事、副总裁兼董事会秘书冯德崎先生等。 股票代码：002019 股票简称：亿帆医药 公告编号：2024-023 亿帆医药股份有限公司 亿帆医药股份有限公司董事会 2024 年 4 月 20 日 为充分尊重投资者、提升交流的针对性，现就公司2023年度业绩说明会提前 向投资者公开 ...

2023 年年度报告全文 2、载有会计师事务所盖章、注册会计师签名并盖章的审计报告原件。 □适用 不适用 四、报告期内召开的年度股东大会和临时股东大会的有关情况 2、表决权恢复的优先股股东请求召开临时股东大会 报告期是否存在任期内董事、监事离任和高级管理人员解聘的情况 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |---------------|-------|-------|-------------------|----------|-------------------------------|-------------------------------|-------------------|--------------------------|--------------------------|---------------------|-------------------|----------------------| | 姓名 | 性别 | 年 龄 | 职务 | 任职状态 | ...